East James Edward, Gordon Morris, Nigam Gaurav Bhaskar, Sinopoulou Vassiliki, Bateman Adrian C, Din Shahida, Iacucci Marietta, Kabir Misha, Lamb Christopher Andrew, Wilson Ana, Al Bakir Ibrahim, Dhar Anjan, Dolwani Sunil, Faiz Omar, Hart Ailsa, Hayee Bu'Hussain, Healey Chris, Leedham Simon John, Novelli Marco R, Raine Tim, Rutter Matthew D, Shepherd Neil A, Subramanian Venkataraman, Vance Margaret, Wakeman Ruth, White Lydia, Trudgill Nigel J, Morris A John
Translational Gastroenterology and Liver Unit, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK
School of Medicine, University of Central Lancashire, Preston, UK.
Gut. 2025 Apr 30. doi: 10.1136/gutjnl-2025-335023.
Patients with inflammatory bowel disease (IBD) remain at increased risk for colorectal cancer and death from colorectal cancer compared with the general population despite improvements in inflammation control with advanced therapies, colonoscopic surveillance and reductions in environmental risk factors. This guideline update from 2010 for colorectal surveillance of patients over 16 years with colonic inflammatory bowel disease was developed by stakeholders representing UK physicians, endoscopists, surgeons, specialist nurses and patients with GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodological support.An a priori protocol was published describing the approach to three levels of statement: GRADE recommendations, good practice statements or expert opinion statements. A systematic review of 7599 publications, with appraisal and GRADE analysis of trials and network meta-analysis, where appropriate, was performed. Risk thresholding guided GRADE judgements.We made 73 statements for the delivery of an IBD colorectal surveillance service, including outcome standards for service and endoscopist audit, and the importance of shared decision-making with patients.Core areas include: risk of colorectal cancer, IBD-related post-colonoscopy colorectal cancer; service organisation and supporting patient concordance; starting and stopping surveillance, who should or should not receive surveillance; risk stratification, including web-based multivariate risk calculation of surveillance intervals; colonoscopic modalities, bowel preparation, biomarkers and artificial intelligence aided detection; chemoprevention; the role of non-conventional dysplasia, serrated lesions and non-targeted biopsies; management of dysplasia, both endoscopic and surgical, and the structure and role of the multidisciplinary team in IBD dysplasia management; training in IBD colonoscopic surveillance, sustainability (green endoscopy), cost-effectiveness and patient experience. Sixteen research priorities are suggested.
尽管先进疗法改善了炎症控制、开展了结肠镜监测并降低了环境风险因素,但与普通人群相比,炎症性肠病(IBD)患者患结直肠癌及死于结直肠癌的风险仍然更高。本2010年结直肠癌监测指南更新版由代表英国医生、内镜医师、外科医生、专科护士以及患者的利益相关者制定,并得到了推荐分级评估、制定与评价(GRADE)方法学的支持。已发布了一份先验方案,描述了针对三个层次声明的方法:GRADE推荐、良好实践声明或专家意见声明。对7599篇出版物进行了系统评价,并在适当情况下对试验进行了评估和GRADE分析以及网状Meta分析。风险阈值指导GRADE判断。我们针对IBD结直肠癌监测服务的提供提出了73条声明,包括服务和内镜医师审核的结果标准,以及与患者共同决策的重要性。核心领域包括:结直肠癌风险、IBD相关的结肠镜检查后结直肠癌;服务组织与支持患者依从性;开始和停止监测、谁应接受或不应接受监测;风险分层,包括基于网络的监测间隔多变量风险计算;结肠镜检查方式、肠道准备、生物标志物和人工智能辅助检测;化学预防;非传统发育异常、锯齿状病变和非靶向活检的作用;发育异常的管理,包括内镜和手术管理,以及多学科团队在IBD发育异常管理中的结构和作用;IBD结肠镜监测培训、可持续性(绿色内镜检查)、成本效益和患者体验。还提出了16项研究重点。